Spots Global Cancer Trial Database for necitumumab
Every month we try and update this database with for necitumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT01763788 | Squamous Non-sm... | Necitumumab Gemcitabine Cisplatin | 20 Years - | Eli Lilly and Company | |
| A Study of LY3023414 and Necitumumab in Squamous Lung Cancer | NCT02443337 | Non-small Cell ... | LY3023414 Necitumumab | 18 Years - | Eli Lilly and Company | |
| A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) | NCT02411591 | Carcinoma, Non-... Neoplasm Metast... | Necitumumab Abemaciclib | 18 Years - | Eli Lilly and Company | |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02941601 | Locally Advance... Metastatic Squa... | Necitumumab Gemcitabine Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors | NCT01624467 | Solid Tumors | Necitumumab | 18 Years - | Eli Lilly and Company | |
| A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | NCT02451930 | Stage IV Non-Sm... | Necitumumab Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | NCT04285671 | Metastatic Lung... Refractory Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Necitumumab Osimertinib Quality-of-Life... Questionnaire A... Trastuzumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer | NCT01769391 | Squamous Non Sm... | Necitumumab Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02941601 | Locally Advance... Metastatic Squa... | Necitumumab Gemcitabine Carboplatin | 18 Years - | Eli Lilly and Company | |
| Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | NCT03054038 | Non-Small Cell ... | Afatinib Necitumumab Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | NCT03387111 | Squamous Cell C... | Aldoxorubicin H... ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK for infusi... Avelumab bevacizumab Capecitabine Cetuximab Cisplatin Cyclophosphamid... Fluorouracil Leucovorin nab-Paclitaxel Necitumumab SBRT N-803 | 18 Years - | ImmunityBio, Inc. | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors | NCT01624467 | Solid Tumors | Necitumumab | 18 Years - | Eli Lilly and Company | |
| A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | NCT02451930 | Stage IV Non-Sm... | Necitumumab Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin | NCT00982111 | Non Small Cell ... | Pemetrexed Cisplatin Necitumumab | 18 Years - | Eli Lilly and Company | |
| Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | NCT03054038 | Non-Small Cell ... | Afatinib Necitumumab Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | NCT03054038 | Non-Small Cell ... | Afatinib Necitumumab Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer | NCT01788566 | Non-small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | NCT02789345 | Non-small Cell ... | Ramucirumab Necitumumab Osimertinib | 18 Years - | Eli Lilly and Company | |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | NCT03944772 | Non-Small Cell ... | Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | NCT03387111 | Squamous Cell C... | Aldoxorubicin H... ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK for infusi... Avelumab bevacizumab Capecitabine Cetuximab Cisplatin Cyclophosphamid... Fluorouracil Leucovorin nab-Paclitaxel Necitumumab SBRT N-803 | 18 Years - | ImmunityBio, Inc. | |
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | NCT04285671 | Metastatic Lung... Refractory Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Necitumumab Osimertinib Quality-of-Life... Questionnaire A... Trastuzumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC | NCT02392507 | Carcinoma, Non-... | Necitumumab Nab-Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
